Document is current
Any future updates will be listed below
-
Authors
Cristiano, Stephen
Leal, Alessandro
Phallen, Jillian
Fiksel, Jacob
Adleff, Vilmos
Bruhm, Daniel C.
Jensen, Sarah Østrup
Medina, Jamie E.
Hruban, Carolyn
White, James R.
Palsgrove, Doreen N.
Niknafs, Noushin
Anagnostou, Valsamo
Forde, Patrick
Naidoo, Jarushka
Marrone, Kristen
Brahmer, Julie
Woodward, Brian D.
Husain, Hatim
van Rooijen, Karlijn L.
Ørntoft, Mai-Britt Worm
Madsen, Anders Husted
van de Velde, Cornelis J. H.
Verheij, Marcel
Cats, Annemieke
Punt, Cornelis J. A.
Vink, Geraldine R.
van Grieken, Nicole C. T.
Koopman, Miriam
Fijneman, Remond J. A.
Johansen, Julia S.
Nielsen, Hans Jørgen
Meijer, Gerrit A.
Andersen, Claus Lindbjerg
Scharpf, Robert B.
Velculescu, Victor E.
- License Information
-
More Information
Article History
Received: 19 November 2018
Accepted: 10 May 2019
First Online: 29 May 2019
Competing interests
: S.C., A.L., J.P., J.F., V. Adleff, R.B.S. and V.E.V. are inventors on patent applications (62/673,516 and 62/795,900) submitted by Johns Hopkins University related to cell-free DNA for cancer detection. V.E.V. is a founder of Delfi Diagnostics and Personal Genome Diagnostics, a member of their Scientific Advisory Boards and Boards of Directors, and owns Delfi Diagnostics and Personal Genome Diagnostics stock, which are subject to certain restrictions under university policy. Within the last five years, V.E.V. has been an advisor to Daiichi Sankyo, Janssen Diagnostics, Ignyta, and Takeda Pharmaceuticals. The terms of these arrangements are managed by Johns Hopkins University in accordance with its conflict of interest policies.
